These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37004981)

  • 1. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
    Dulucq S; Rigal-Huguet F; Nicolini FE; Cony-Makhoul P; Escoffre-Barbe M; Gardembas M; Legros L; Rousselot P; Liu J; Rea D; De Mas V; Hayette S; Raynaud S; Lacoste-Roussillon C; Robbesyn F; Klein E; Morisset S; Mahon FX; Etienne G
    Br J Haematol; 2023 Jun; 201(6):1116-1124. PubMed ID: 37004981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
    Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
    Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
    Cony-Makhoul P; Gardembas M; Coiteux V; Carpentier N; Pommier C; Violet I; Quittet P; Berger MG;
    Br J Haematol; 2018 Feb; 180(3):356-364. PubMed ID: 29265184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e138-e141. PubMed ID: 38195325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.
    Rios SJ; Martínez-Montesinos L; Aroca C; Teruel-Montoya R; Ferrer-Marín F
    J Assist Reprod Genet; 2020 Oct; 37(10):2473-2476. PubMed ID: 32766925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].
    Turkina AG; Chelysheva EY; Shuvaev VA; Gusarova GA; Bykova AV; Shukhov OA; Petrova AN; Vakhrusheva MV; Goryacheva SR; Kolosova LY; Krasikova PS; Fominykh MS; Martynkevich IS; Abdullaev AO; Sudarikov AB; Savchenko VG
    Ter Arkh; 2017; 89(12):86-96. PubMed ID: 29411766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
    Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
    Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
    Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic of liver enzymes and serum electrolytes in HCV, HBV, and HIV negative chronic phase chronic myeloid leukemia patients treated with imatinib or nilotinib.
    Abdel Hammed MR; Nafady HA; Mohamed NM; Abd Elkader AS
    Egypt J Immunol; 2023 Apr; 30(2):59-72. PubMed ID: 37031398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.